KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Development of lymphatic drug delivery platforms for the treatment of carcinomas

    Thumbnail
    View/Open
    Cai_ku_0099D_11596_DATA_1.pdf (6.107Mb)
    Issue Date
    2011-05-31
    Author
    Cai, Shuang
    Publisher
    University of Kansas
    Format
    269 pages
    Type
    Dissertation
    Degree Level
    Ph.D.
    Discipline
    Pharmaceutical Chemistry
    Rights
    This item is protected by copyright and unless otherwise specified the copyright of this thesis/dissertation is held by the author.
    Metadata
    Show full item record
    Abstract
    Many cancers, such as breast cancer, lung cancer, and head and neck cancer, preferentially metastasize via the lymphatic system prior to their systemic invasion. Conventional chemotherapy has limited penetration into the lymphatics due to its anatomy, because drug molecules have to diffuse from the blood capillaries into the surrounding tissues and further enter the lymph vessels to reach the diseased lymph nodes. Therefore, chemotherapy can be of limited benefit in treating lymph node disease. In addition, due to the systemic administration and wide distribution, conventional intravenous chemotherapy causes a variety of organ toxicities, including but not limited to: renal toxicity, cardiotoxicity, and hepatic toxicity. This limits its use in the clinic, expecially for the elderly or late-stage patients who cannot tolerate systemic toxicities. Therefore, there is a critical need to develop of a localized drug delivery platform that confines the anti-cancer drugs to the site of the disease. This dissertation focuses on the development of subcutaneously delivered drug platforms for the treatment of cancers that are known to be lymphatically metastatic. The goal is to improve the anti-cancer efficacy and reduce the non-specific organ toxicities of small molecule chemotherapeutic agents. To achieve this goal, three polymer-based anti-cancer conjugates: hyaluronan-cisplatin (HA-Pt), hyaluronan-doxorubicin (HA-DOX), and sugar star polymer-nitric oxide prodrug 1 (sugar-NO1), were synthesized, characterized, and evaluated in preclinical rodent models. The route of drug administration along with the controlled release of the drug from the platforms, both play an important role in improving the biopharmaceutical properties of these conjugates. This is demonstrated by the extended systemic rentention, as well as the elevated local accumulation of the drug in the draining lymph nodes of the tumor, when compared to standard intravenous chemotherapy. The HA-Pt and HA-DOX conjugates exhibited reduced renal toxicity and cardiotoxicity, respectively, relative to the conventional intravenous chemotherapy in rats. Because of the improved pharmarcokinetic and toxicological profiles of the polymer-drug conjugates, animals that were treated with the subcutaneous conjugates demonstrated enhanced inhibition of the tumor progression and increased survival rates. To understand the increased anti-cancer activity of the conjugates on a cellular level, the interaction and internalization of the nanocarriers into tumor cells was also investigated using a gold nanoparticle tagged HA-Pt conjugate and a fluorescently labeled HA-DOX conjugate. In the clinic, cisplatin and doxorubicin are often administered in combination with other anti-tumor agents as a "chemo cocktail" to prevent chemoresistance. Additionally, nitric oxide has been shown to improve the cytotoxicity of cisplatin therapy via a synergistic effect. Therefore, the development of a nitric oxide prodrug cisplatin combinational therapy, with increased anti-proliferative activity against cancer cells, was investigated; and it is also presented in this disssertation and compared to cisplatin treatment alone. In conclusion, this thesis work has led to the successful preclinical development of two localized drug delivery platforms and one promising candidate for the treatment of metastatic carcinomas. The motivation for drug delivery scientists to develop more efficacious and less toxic chemotherapies will be presented.
    URI
    http://hdl.handle.net/1808/10703
    Collections
    • Dissertations [4475]
    • Pharmaceutical Chemistry Dissertations and Theses [141]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps